Two Pregabalin lots recalled in Canada over contamination with another drug
Latest news on WhatsApp أجدد الأخبار على واتساب
Health Canada has issued a public health advisory after Teva Canada recalled two lots of Teva-Pregabalin 150 mg capsules nationwide following routine testing that found some capsules may be contaminated with sertraline.
The recall affects lot numbers 100070495 and 100068913, both with an expiry date of July 31, 2027. Products from the affected lots were first sold in Canada in September 2025, and Health Canada says it is monitoring the company's recall and corrective measures.
Pregabalin is a prescription medication used in adults to treat certain types of nerve pain linked to diabetes, shingles and spinal cord injury, as well as pain associated with fibromyalgia.
Sertraline is prescribed for conditions including depression, obsessive-compulsive disorder and panic disorder.
Health Canada warns that people who are hypersensitive or allergic to sertraline could experience side effects or a serious allergic reaction, including anaphylaxis, even at low exposure. Symptoms can include difficulty breathing, swelling of the face, lips, tongue or throat, dizziness, fainting and widespread rash or hives.
Patients are advised not to suddenly stop taking pregabalin without first speaking with a healthcare professional or pharmacist, as abrupt discontinuation may cause withdrawal symptoms. Affected products should be returned to the pharmacy for replacement, while anyone experiencing a severe allergic reaction should seek emergency medical help immediately.
